Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics

Neuropsychiatric Disease and Treatment

Volumn 3, Issue 3, 2007, Pages 303-333

  Cacabelos, Ramón ^a,b  

^a Centro de Investigacion Biomedica EuroEspes   (Spain)

^b CAMILO JOSÉ CELA UNIVERSITY   (Spain)

Author keywords

Alzheimer's disease; CNS disorders; CYP2D6 Pharmacogenetics; Donepezil; Pharmacodynamics; Pharmacokinetics; Vascular dementia

Indexed keywords

ACETYLCHOLINE; ALPHA TOCOPHEROL; CARBIDOPA; CHOLINESTERASE INHIBITOR; CIMETIDINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DIGOXIN; DONEPEZIL; FUROSEMIDE; GALANTAMINE; GINKGO BILOBA EXTRACT; GLUTAMIC ACID; INTERLEUKIN 1; LEVODOPA; MEMANTINE; METRIFONATE; ONCOSTATIN M; PHENSERINE; PHYSOSTIGMINE; PLACEBO; PROTEIN P21; RISPERIDONE; RIVASTIGMINE; SERTRALINE; TACRINE; THEOPHYLLINE; UNINDEXED DRUG; WARFARIN;

ABDOMINAL PAIN; ALZHEIMER DISEASE; ANOREXIA; ANXIETY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BEHAVIOR CHANGE; BLOATING; BRAIN ATROPHY; CARDIOVASCULAR DISEASE; CATATONIA; CELL CYCLE G2 PHASE; CLINICAL TRIAL; COGNITIVE THERAPY; COMMON COLD; CONFUSION; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; CYSTITIS; DELIRIUM; DEPRESSION; DIAGNOSTIC IMAGING; DIARRHEA; DISEASE COURSE; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DIZZINESS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG METABOLISM; DRUG SAFETY; ENZYME ACTIVITY; ENZYME INHIBITION; EXCRETION; EXTRAPYRAMIDAL SYMPTOM; FALLING; FATIGUE; GASTROENTERITIS; HALLUCINATION; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; LIVER DYSFUNCTION; MAXIMUM PLASMA CONCENTRATION; METABOLIC DISORDER; MONOTHERAPY; MULTIINFARCT DEMENTIA; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; NAUSEA; NERVE DEGENERATION; NEUROLEPTIC MALIGNANT SYNDROME; NEUROPROTECTION; NIGHTMARE; NONHUMAN; NOSE CONGESTION; PANCREATITIS; PATHOGENESIS; PHARMACOGENETICS; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PROTEIN BINDING; QUALITY OF LIFE; RESTLESSNESS; SEIZURE; SIDE EFFECT; SKIN DISEASE; SYNCOPE; TARDIVE DYSKINESIA; TOXIC HEPATITIS; URINARY TRACT INFECTION; UROGENITAL TRACT DISEASE; VERTIGO; VOMITING; WEIGHT REDUCTION;

EID: 34547667531     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (257)

1. Adunsky A, Chesnin V, Ravona R, et al. 2004. Plasma lipid levels in Alzheimer's disease patients treated with donepezil hydrochloride: a cross-sectional study. Arch Gerontol Geriatr, 38:61-8.
2. Aerssens J, Raeymaekers P, Lilienfeld S, et al. 2001. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease. Dentent Geriatr Cogn Disord, 2:69-77.
3. Aguglia E, OnoT ML, Saina K et al. 2004. An open-label comparative study of rivastigmine, donepezil and galantamine in a real-world setting. Curr Med Res, 20:1747-52.
4. Akasofu S, Kimura M, Kosasa T, et al. 2006. Protective effect of donepezil in primary-cultured rat cortical neurons exposed to N-methyl-d-aspartate (MMDA) toxicity. Eur J Pharmacol, 530:215-22.
5. Almkvist O, Jelic V, Amberla K, et al. 2001. Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine m Alzheimer patients. Dentent Geriatr Cogn Disord, 12:22-32.
6. Alvarez XA, Mouzo R, Pichel V, et al. 1999. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity, and cerebral perfusion. Meth Find Exp Clin Pharmacol, 21:633-44.
7. Alvarez XA, Pichel V, Pérez PA, et al. 2000. Double-blind, randomized, placebo-controlled pilot study with anapsos in senile dementia: effects on cognition, brain bioelectrical activity and cerebral hemodynamics. Meth Find Exp Clin Pharmacol, 22:585-94.
8. Ancoli-Israel S, Amatniek J, Ascher S, et al. 2005. Effects of galantamine versus donepezil on sleep in patients with mild to moderate Alzheimer disease and their caregivers: a double-blind, head-to-head, randomized pilot study. Alzheimer Dis Assoc Disord, 19:240-5.
9. Arias E, Gallego-Sandin S, Villaroya M, et al. 2005. Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors. J Pharmacol Exp Ther, 315:1346-53.
10. Arinzon Z, Peisakh A, Zuta A, et al. 2006. Drug use in a geriatric long-term care setting. Comparison between newly admitted and institutionalised patients. Drugs Aging, 23:157-65.
11. Babic T, Lakusic DM, Sertic J, et al. 2004. ApoE genotyping and response to galanthamine in Alzheimer's disease - a real life retrospective study. Coll Antropol 28:199-204.
12. Babic T, Zurak N. 1999. Convulsions induced by donepezil. J Neurol Neurosurg Psychiatry, 66:410.
13. Barak Y, Bodner E, Zemishlani H, et al. 2001. Donepezil for the treatment of behavioral disturbances in Alzheimer's disease: a 6-month open trial. Arch Gerontol Geriatr, 33:237-41.
14. Bartus RT, Dean RL 3rd, Beer B, et al. 1982. The cholinergic hypothesis of geriatric memory dysfunction. Science, 217:408-17.
15. Beglinger LJ, Tangphao-Daniels O, Kareken DA, et al. 2005. Neuropsychological test performance in healthy elderly volunteers before and after donepezil administration: a randomized, controlled trial. J Clin Psychopharmacol, 25:159-65.
16. Benazzi F. 1999. Mania associated with donepezil. J Psychiatry Neurosci, 24:468-9.
17. Bentué-Ferrer D, Tribut O, Polard E, et al. 2003. Clinically significant drug interactions writh cholinesterase inhibitors. CNS Drugs, 17:947-63.
18. Bergman J, Brettholz I, Shneidman M, et al. 2003. Donepezil as add-on treatment of psychotic symptoms in patients with dementia of the Alzheimer's type. Clin Neuropharmacol, 26:88-92.
19. Bernard S, Neville KA, Nguyen AT, et al. 2006. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: Clinical implications. Oncologist 11: 126-35.
20. Beusterien KM, Thomas SK, Gause D, et al. 2004. Impact of rivastigmine use on the risk of nursing home placement in a US sample. CNS Drugs, 18:1143-8.
21. Bianchetti A, Rozzini R, Trabucchi M. 2003. Effects of acetyl-L-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors. Curr Med Res Opin, 19:350-3.
22. Birks J. 2006. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev, CD005593.
23. Birks J, Harvey R. 2006. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev, CD001190.
24. Bizzarro A, Marra C, Acciarri A, et al. 2005. Apolipoprotein E epsilon-4 allele differentiates the clinical response to donepezil in Alzheimer's disease. Demerit Geriatr Cogn Disord, 20:254-61.
25. Black S, Roman GC, Geldmacher DS, et al. 2003. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke, 34:2323-30.
26. Blasko I, Bodner T, Knaus G, et al. 2004. Efficacy of donepezil treatment in Alzheimer patients with and without subcortical vascular lesions. Pharmacology, 72:1-5.
27. BohnenNI, Kaufer Dl, Hendrickson R, et al. 2005. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. J Neurol Neurosurg Psychiatry, 76:315-9.
28. Bordier P, Lanusse S, Garrigue S, et al. 2005. Causes of syncope in patients with Alzheimer's disease treated with donepezil. Drugs Aging, 22:687-94.
29. Borroni B, Agosti C, Martini G, et al. 2005. Cholinesterase inhibitors exert a protective effect on endothelial damage in Alzheimer disease patients. J Neurol Sci, 229-230:211-13.
30. Borroni B, Colciaghi F, Pastorino L, et al. 2002. ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral model. Eur Neuropsychopharmacol, 72:195-200.
31. Borroni B, Pettenati C, Bordonali T, et al. 2003. Serum cholesterol levels modulate long-term efficacy of cholinesterase inhibitors in Alzheimer disease. Neurosci Lett, 343:213-5.
32. Bossy-Wetzel E, Scharzenbacher R, Lipton SA. 2004. Molecular pathways to neurodegeneration. Nature Medicinel/Neurodegeneration Suppl, S2-S9 [online] July 1, 2004; doi: 10.1038/nm1067.
33. Bouman WP, Pinner G. 1998. Violent behavior-associated with donepezil. Am J Psychiatry, 155:1626-7.
34. Bryant CA, Ouldred E, Jackson SH, et al. 1998. Purpuric, rash with donepezil treatment. BMJ, 317:787.
35. Bryson HM, Benfield P. 1997. Donepezil. Drugs Aging, 10:234-9.
36. Bullock R, Bergman H, Touchon J, et al. 2006. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. Curr Med Res Opin, 22:483-94.
37. Bullock R, Dengiz A. 2005. Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years. Int J Clin Pract, 59:817-22.
38. Bullock R, Touchon J, Bergman H, et al. 2005. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin, 21:1317-27.
39. Burns A, Rossor M, Hecker J, et al. 1999. The effects of donepezil in Alzheimer's disease-results from a multinational trial. Demerit Geriatr Cogn Disord, 10:237-44.
40. Cacabelos R, 2002a. Pharmacogenomics in Alzheimer's disease. Min Rev Med Chem, 2:59-84.
41. Cacabelos R, 2002b. Pharmacogenomics for the treatment of dementia. Ann. Med, 34: 357-79.
42. Cacabelos R, 2003. The application of functional genomics to Alzheimer's disease. Pharmacogenomics, 4:597-621
43. Cacabelos R, 2004. Genomic characterization of Alzheimer's disease and genotype-related phenotypic analysis of biological markers in dementia. Pharmacogenomics, 58:1049-105.
44. Cacabelos R, 2005a Pharmacogenomics and therapeutic prospects in Alzheimer's disease. Exp. Opin. Pharmacother, 6:1967-87.
45. Cacabelos R, 2005b. Phannacogenomics, nutrigenomics and therapeutic optimization in Alzheimer's disease. Aging Health, 1: 303-48.
46. Cacabelos R, 2007. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression. Meth Find Exper Clin Pharmacol, 29 (SuppI B): 1-91.
47. Cacabelos R, Alvarez A, Fernández-Novoa L, et al. 2000a. A pharmacogenomic approach to Alzheimer's disease. Acta Neurol Scand, 176(Suppl.)-.12-19.
48. Cacabelos R, Alvarez XA, Lombardi V, et al. 2000b. Pharmacological treatment of Alzheimer disease: From phychotropic drugs and cholinesterase inhibitors to pharmacogenomics. Drugs Today, 36:415-99.
49. Cacabelos R, Fernández-Novoa L, Lombardi V, et al. 2003. Cerebrovascular risk factors in Alzheimer's disease: Brain hemodynamics and pharmacogenomic implications. Neurol Res, 25:567-80.
50. Cacabelos R, Fernández-Novoa L, Corzo L, et al. 2004a. Phenotypic profiles and functional genomics in dementia with a vascular component. Neurol Res, 26:459-80.
51. Cacabelos R, Fernández-Novoa L, Corzo L, et al. 2004b. Genomics and phenotypic profiles in dementia: Implications for pharmacological treatment. Meth Find Exper Clin Pharmacol, 26:421-44.
52. Cacabelos R, Fernández-Novoa L, Lombardi V, et al. 2005. Molecular genetics of Alzheimer's disease and aging. Genomic Medicine Series. Part 1. Meth Find Exper Clin Pharmacol, 27 (Suppl A): 1-573.
53. Cacabelos R, Fernández-Novoa L, Pichel V, et al. 2004c. Pharmacogenomic studies with a combination therapy in Alzheimer's disease. In Takeda M, Tanaka T, Cacabelos R (eds). Molecular Neurobiology of Alzheimer Disease and Related Disorders. Basel: Karger, Basel. p. 94-107.
54. Cacabelos R, Niigawa H, Ikemura T, et al 1988a. GHRH- induced GH response in patients with senile dementia of the Alzheimer type. Acta Endocrinol (Copenh), 117:295-301.
55. Cacabelos R, Niigawa H, Rodríguez-Arnao MD, et al. 1988b. Influence of somatostatin and growth hormone-releasing factor on behavior. Clinical and therapeutic implications in neuropsychiatric disorders. Horm Res, 29:129-32.
56. Cacabelos R, Rodríguez B, Carrera C, et al. 1996. APOE-related dementia symptoms: frequency and pregression. Ann Psychiatry, 6:189-205.
57. Cacabelos R, Rodriguez B, Carrera C, et al. 1997. Behavioral changes associated with different apolipoprotein E genotypes in dementia. Alzheimer's Dis Assoc Dis, 11(Suppl 4):S27-S37.
58. Cacabelos R, Takeda M. 2006. Pharmacogenomics, nutrigenomics and future therapeutics in Alzheimer's disease. Drugs Future, 31 (Suppl B):5-146.
59. Cacabelos R, Takeda M, Winblad B. 1999. The glutamatergic system and neurodegeneration in dementia: Preventive strategies in Alzheimer's disease. Int J Geriat Psychiatry, 14:3-47.
60. Capsoni S, Giannotta S, Stebel M, et al. 2004. Ganstigmine and donepezil improve neurodegeneration in AD11 antinerve growth factor transgenic mice. Am J Alzheimer Dis Other Demen, 19:153-60.
61. Carcenac D, Martin-Hunyadi C, Kiesmann M, et al. 2000. Extrapyramidal syndrome induced by donepezil. Press Med, 29:992-3.
62. Clegg A, Bryant J, Nicholson T, et al. 2001. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. Health Technol Assess, 5:1-137.
63. Courtney C, Farrell D, Gray R, et al. 2004. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet, 363:2105-15.
64. Crowe S, Collins L. 2003. Suxamethonium and donepezil: a cause of prolonged paralysis. Anesthesiology, 98:574-5.
65. Csernansky JG, Wang L, Miller JP, et al. 2005. Neuroanatomical predictors of response to donepezil therapy in patients with dementia. Arch Neurol, 62:1718-22.
66. Di Angelantonio S, Bernardi G, Mercuri NB. 2004. Donepezil modulates nicotinic receptors of substantia nigra dopaminergic neuronas. Br J Pharmacol, 141:644-52.
67. Dickerson BC, Sperling RA. 2005. Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease. NeuroRx, 2:348-60.
68. Dong H, Csernansky CA, Martin MV, et al. 2005. Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease. Psychopharmacology (Berl), 181:145-52.
69. Doody RS. 1999. Clinical profile of donepezil in the treatment of Alzheimer's disease. Gerontology, 45 (Suppl 1):23-32.
70. Doody RS. 2005. Refining treatment guidelines in Alzheimer's disease. Geriatrics, (Suppl): 14-20.
71. Doody RS, Dunn JK, Clark CM, et al. 2001b. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord, 12:295-300.
72. Doody RS, Geldmacher DS, Gordon B, et al, Donepezil Study Group. 2001 a. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol, 58:427-33.
73. Dunn NR, Pearce GL, Shakir SA. 2000. Adverse effects associated with the use of donepezil in general practice in England. J Psychopharmacol, 14:406-8.
74. Erkinjuntti T, Kurz A, Gauthier S, et al. 2002. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial. Lancet, 359:1283-90.
75. Erkinjuntti T, Roman G, Gauthier S, et al. 2004. Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke, 35:1010-17.
76. Evans WE, McLeod HL. 2003. Pharmacogenomics-Drug disposition, drug targets, and side effects. N Engl J Med 348:538-49.
77. Farlow MR. 2001. Phamiacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galantamine. Clin Ther, 23 (Suppl A):A13-24.
78. Farlow MR. 2003. Clinical pharmacokinetics of galantamine. Clin Pharmacokinet 42:1383-92.
79. Feldman H, Gauthier S, Hecker J, et al. 2001. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimr's disease. Neurology, 57:613-20.
80. Feldman H, Gauthier S, Hecker J, et al. 2003. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on cargiver burden. J Am Geriar Soc, 51:737-44.
81. Feldman H, Gauthier S, Hecker J, et al. 2004. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology, 63:644-50.
82. Feldman H, Gauthier S, Hecker J, et al. 2005. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial. Int J Geriatr Psychiatry, 20:559-69.
83. Fillit HM. 2000. The pharmacoeconomics of Alzheimer's disease. Am J Manag Care, 6 (Suppl 22):S 1139-44.
84. Finkel SI, Mintzer JE, Dysken M, et al. 2004. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. Int J Geriatr Psychiatry, 19:9-18.
85. Forchetti CM. 2005. Treating patients with moderate to severe Alzheimer's disease: implications of recent pharmacologic studies. Prim Care Companion J Clin Psychiatry, 7:155-61.
86. Francis PT, Palmer AM, Snape M, et al. 1999. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry, 66:137-47.
87. Fukui T, Taguchi S. 2005. Do vascular lesions and related risk factors influence responsiveness to donepezil chloride in patients with Alzheimer's disease? Demerit Geriatr Cogn Disord, 20:15-24.
88. Gasper MC, Ott BR, Lapane KL. 2005. Is donepezil therapy associated with reduced mortality in nursing home residents with dementia? Am J Geriatr Pharmacother, 3:1-7.
89. Gauthier SG. 2005, Alzheimer's disease: the benefits of early intervention. Eur J Neurol, 12 (Suppl 3):11-6.
90. Gauthier S, Feldman H, Hecker J, et al. 2002a. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Curr Med Res Opin, 18:347-54.
91. Gauthier S, Feldman H, Hecker J, et al. 2002b. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatr, 14:389-404.
92. Geerts H, Guillaumat PO, Grantham C, et al. 2005. Brain levels and acetyl-cholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits. Brain Res, 1033:186-93.
93. Geldmacher DS, Provenzano G, McRae T, et al. 2003. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc, 51:937-44.
94. Giacobini E. 2000. Cholinesterases and cholinesterase inhibitors. Martin Dunitz, London.
95. Giacobini E. 2006. Cholinesterases in human brain: the effect of cholinesterase inhibitors on Alzheimer's disease and related disorders. In Giacobini E, Pepeu G (eds). The Brain Cholinergic System in Health and Disease. Oxon: Informa Healthcare. p 235-264.
96. Giacobini E, Zhu XD, Williams E, et al. 1996. The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex. Neuropharmacology, 35:205-11.
97. Gill SS, Bronskill SE, Mamdani M, et al. 2004. Representation of patients with dementia in clinical trials of donepezil. Can J Clin Pharamcol, 11:e274-85.
98. Gill SS, Rochon PA, Herrmann N, et al. 2005. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ, 330:445. Doi:10.1136/bmj.38330.470486.8F.
99. Goedert M, Spillantini MG. 2006. A century of Alzheimer's disease. Science, 314:777-81.
100. Goldsmith DR, Scott LJ. 2003. Donepezil: in vascular dementia. Drugs Aging, 20:1127-36.
101. Greenberg SM, Tennis MK, Brown LB, et al. 2000. Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol, 57:94-9.
102. Harry RD, Zakzanis KK. 2005. A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis. Hum Psychopharmacol, 20:183-7.
103. Hashimoto M, Imamura T, Tanimukai S, et al. 2000. Urinary incontinence: an unrecognized adverse effect with donepezil. Lancet, 356:568.
104. Hashimoto M, Kazui H, Matsumoto K, et al. 2005. Does donepezil treatment show the progression of hippocamnpal atrophy in patients with Alzheimer's disease? Am J Psychiatry, 162:676-82.
105. Haugh KE, Bogen IL, Osmundsen H, et al. 2005. Effects of cholinergic markers in rat brain and blood after short and prolonged administration of donepezil. Neurochem Res, 30:1511-20.
106. Heydorn WE. 1997. Donepezil (E2020): a new acetylcholinesterase inhibitor. Review of its pharmacology, pharmacokinetics, and utility in the treatment of Alzheimer's disease. Expert Opin Investg Drugs, 6:1527-35.
107. Hirono N, Hashimoto M, Ishii K, et al. 2004. One-year change in cerebral glucose metabolism in patients with Alzheimer's disease. J Neuropsychiatry Clin Neurosci, 16:488-92.
108. Hogan DB, Goldlist B, Naghe G, et al. 2004. Comparison studies of cholinesterase inhibitors for Alzheimer's disease. Lancet Neurol, 3:622-628.
109. Holmes C, Wilkinson D, Dean C, et al. 2004. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology, 63:214-9.
110. Homma A, Takeda. M, Imai Y, et al. 2000. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Dement Geriatr Cogn Disord, 11:299-313.
111. International Human Genome Sequencing Consortium. 2004. Finishing the euchromatic sequence of the human genome. Nature, 431:931-45.
112. Isaza CA, Henao J, López AM, et al. 2000. Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population. Meth Find Exp Clin Pharmacol, 22:695-705.
113. Jackson S, Hain RJ, Wilkinson D. 2004. The safety and tolerability of donepezil in patients with Alzheimer's disease. Br J Clin Pharmacol, 58 (Suppl 1): 1-8.
114. Jacobsen FM, Coma-Diaz L. 1999. Donepezil for psychotropic-induced memory loss. J Clin Psychiatry, 60:698-704.
115. Jagust W 2004. Molecular neuroimaging in Alzheimer's disease. NeuroRx, 1:206-12.
116. Jann MW, Shirley KL, Small GW. 2002. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet, 41:719-39.
117. Jelic V, Kivipelto M, Winblad B. 2005. Clinical trials in mild cognitive impairment: lessons for the future. J Neurol Neurosurg Psychiatry, 23 Nov; doi:10.1136/jnnp.2005.072926.
118. Kaasinen V, Nagren K, Jarvenpaa T, et al. 2002. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J Clin Psychopharmacol, 22:615-20.
119. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, et al. 2005. Cholinesterase inhibitors for patients with Alzheimer's disease: a systematic review of randomized clinical trials. BMJ, 331:321-7.
120. Kaiser T, Florack C, Franz H, et al. 2005. Donepezil in patients with Alzheimer's disease - a critical appraisal of the AD2000 study. Med Klin, 100:157-60.
121. Kalow W, Grant DM. 2001. Pharmacogenetics. In Scriver CR, Beaudet AL, Sly WS, et al (eds). The Metabolic & Molecular Bases of Inherited Disease. New York, NY. McGraw-Hill. p.225-55.
122. Kemp PM, Holmes C, Hoffmann S, et al. 2003. A randomized controlled study to assess the effects of cholinergic treatment on muscarinic receptors in Alzheimer's disease. J Neurol Neurosurg Psychiatry, 74:1567-70.
123. Kimura M, Akasofu S, Ogura H, et al. 2005. Protective effect of donepezil against Abeta(1-40) neurotoxicity in rat septal neurons. Brain Res, 1047:72-84.
124. Kinney GG, Patino P, Mermet-Bouvier Y, et al. 1999. Cognition-enhancing drugs increase stimulated hippocapal theta rhythm amplitude in the urethane-anesthetized rat. J Pharmacol Exp Ther, 291:99-106.
125. Kirshner HS. 2005. Mild cognitive impairment: to treat or not to treat. Curr Neurol Neurosci Rep, 5:455-7.
126. Klatte ET, Scharre DW, Nagaraja HN, et al. 2003. Combination therapy of donepezil and vitamine E in Alzheimer disease. Alzheimer Dis Assoc Disord, 17:113-6.
127. Kogan EA, Korczyn AD, Virchovsky RG, et al. 2001. EEG changes during long-term treatment with donepezil in Alzheimer's disease patients. J Neural Transm, 108:1167-73.
128. Kosasa T, Kuriya Y, Matsui K, et al. 1999. Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats. Eur J Pharmacol, 380:101-7.
129. Krishnan KR, Charles HC, Doraiswamy PM, et al. 2003. Randomized, placebo-controlled trial of the effects of donepzil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry, 160:2003-11.
130. Kume T, Sugimoto M, Tanaka Y, et al. 2005. Up-regulation of nicotinic acetylcholine receptors by central-type acetylcholinesterase inhibitors in rat cortical neurons. Eur J Pharmacol, 527:77-85.
131. Kwak YT, Han IW, Baik J, et al. 2000. Relation between cholinesterase inhibitor and Pisa syndrome. Lancet, 355:2222.
132. Lanctôt KL, Herrmann N, Yau KK, et al. 2003. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ, 169:557-64.
133. Levy ML, Cummings JL, Kahn-Rose R. 1999. Neuropsychitric symptoms and cholinergic therapy for Alzheimer's disease. Gerontology, 45:15-22.
134. Li W, Pi R, Chan HH, et al. 2005. Novel dimeric acetylcholinesterase inhibitor bis7-tacrine, but not donepezil, prevents glutamate-induced neuronal apoptosis by blocking N-methyl-D-aspartate receptors. J Biol Chem, 280:18179-88.
135. Lingler JH, Martire LM, Schulz R. 2005. Caregiver-specific outcomes in antidementia clinical drug trials: a systematic review and meta-analysis. J Am Geriatr Soc, 53:983-90.
136. Liu HC, Lin SK, Sung SM. 2002. Extrapyramidal side-effects due to drug combination of risperidone and donepezil. Psychiatry Clin Neurosci, 5:479.
137. Loveman E, Green C, Kirby J, et al. 2006. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol Assess, 10:1-176.
138. MacGowan SH, Wilcock GK, Scott M. 1998. Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease. Int J Geriatr Psychiatry, 13:625-30.
139. Magnuson TM, Keller BK, Burke WJ. 1998. Extrapyramidal side effects in a patient treated with risperidone plus donepezil. Am J Psychiatry, 155:1458-9.
140. Maguire GA. 2000. Impact of antypsychotics on geriatric patients: efficacy, dosing, and compliance. Prim Care Comp J Clin Psychiatry, 2:165-72.
141. Malouf R, Birks J. 2004. Donepezil for vascular cognitive impairment. Cochrane Database Syst Rev, CD004395.
142. Mannens GS, Snel CA, Hendrickx J, et al. 2002. The metabolism and excretion of galantamine in rats, dogs, and humans. Drug Metab Dispos, 30:553-63.
143. Masterman DL. 2004. Role of cholinesterase inhibitors in managing behavioral problems in Alzheimer's disease. Prim Care Companion J Clin Psychiatry, 6:126-31.
144. Masuda Y, Kawamura A. 2003. Acetylcholinesterase inhibitor (donepezil hydrochloride) reduces heart rate variability. J Cardiovasc Pharmacol, 41 (Suppl 1):S67-71.
145. Matsui K, Mishima M, Nagai Y, et al. 1999. Absorption, distribution, metabolism, and excretion of donepezil (Aricept) after a single oral administration to rat. Drug Metab Dispos, 27:1406-14.
146. Matthews HP, Korbey J, Wilkinson DG, et al. 2000. Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic. Int J Geriat Psychiatry, 15:713-20.
147. Maurice T, Meunier J, Feng B, et al. 2006, Interaction with sigma1 protein, but not NMDA receptors, is involved in the pharmacological activity of donepezil. J Pharmacol Exp Ther, Jan 5 (Epub ahead of print).
148. McLaren AT, Allen J, Murray A, et al. 2003. Cardiovascular effects of donepezil in patients with dementia. Dement Geriatr Cogn Disord, 15:183-8.
149. McMahon PM, Araki SS, Neumann PJ, et al. 2000. Cost-effectiveness of functional imaging tests in the diagnosis of Alzheimer's disease. Radiology, 217:58-68.
150. Miyaoka T, Seno H, Yamamori C, et al. 2001. Pisa syndrome due to a cholinesterase inhibitor (donepezil): a case report. J Clin Psychiatry, 62:573-4.
151. Mizuno S, Kameda A, Inagaki T, et al. 2004. Effects of donepezil on Alzheimer's disease: the relationship between cognitive function and rapid eye movement sleep. Psychiatry Clin Neurosci, 58:660-5.
152. Mohs RC, Doody RS, Morris JC, et al. 2001. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology, 57:481-8.
153. Moraes WS, Poyares DR, Guilleminault C, et al. 2006. The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double-blind placebo-controlled study. Sleep, 29:199-205.
154. Moriguchi S, Zhao X, Marszalec W, et al. 2005. Modulation of N-methyl-D-aspartate receptors by donepezil in rat cortical neurons. J Pharmacol Exp Ther, 315:125-35.
155. Murman DL, Chen Q, Powell MC, et al. 2002. The incremental direct costs associated with behavioral symptoms in AD. Neurology, 59:1721-9.
156. Nagy CF, Kumar D, Perdomo CA, et al. 2004. Concurrent administration of donepezil and sertraline in healthy volunteers: assessment of pharmacokinetic changes and safety following single and multiple oral doses. Br J Clin Pharamcol, 58(Suppl 1):25-33.
157. Nakano S, Asada T, Matsuda H, et al. 2001, Donepezil hydrochloride preserves regional cerebral flor in patients with Alzheimer's disease. J Nucl Med, 42:1441-5.
158. Nebert DW, Jorge-Nebert LF. 2002. Pharmacogenetics and pharmacogenomics. In Connor JM, Pyeritz R, Korf BR, et al (eds). Emery and Rimoin's Principles and Practice of Medical Genetics. 4th ed. Edinburgh: Churchill -Livingstone, p.590-631.
159. Nissen C, Nofzinger EA, Feige B, et al. 2006. Differential effects of the muscarinic M1 receptor agonist RS-86 and the acetylcholine-esterase inhibitor donepezil on REM sleep regulation in healthy vlounteers. Neuropsychopharmacol, 31:1294-300.
160. Nobili F, Vitali P, Canfura M, et al. 2002. Effects of long-term donepezil therapy on rCBF of Alzheimer's patients. Clin Neurophysiol, 113:1241-8.
161. Nochi S, Asakawa N, Sato T. 1995. Kinetic study on the inhibition of acetylcholinesterase by 1-benzyl-4-[(5,&Ah-ethoxy-1-indanon)-2-yl)methylpiperidine hydrochloride (E2020). Biol Pharm Bull, 18:1145-7.
162. Nordberg A, Svensson AL. 1998. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Saf 19:465-80.
163. Obermayr RP, Mayerhofer L, Knechtelsdorfer M, et al. 2005. The age-related down-regulation of the growth hormone/insulin-like growth factor-1 axis in the elderly male is reversed considerably by donepezil, a drug for Alzheimer's disease. Exp Gerontol, 40:157-63.
164. Ogura H, Kosasa T, Kuriya Y, et al. 2000. Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. Meth Find Exp Clin Pharmacol, 22:609-13.
165. Ohkoshi N, Satoh D, Nishi M, et al. 2003. Neuroleptic malignat-like syndrome due to donepezil and maprotiline. Neurology, 60:1050-1.
166. Ohnishi A, Mihara M, Kamakura H, et al. 1993. Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. J Clin Pharmacol, 33:1086-91.
167. Okereke CS, Kirby L, Kumar D, et al. 2004. Concurrent administration of donepezil and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. Br J Clin Pharmacol, 58 (Suppl 1):41-9.
168. Paci C, Gobbato R, Carboni T, et al. 2006. P300 auditory event-related potentials and neuropsychological study during donepezil treatment in vascular dementia. Neurol Sci, 26:435-7.
169. Pakaski M, Rakonczay Z, Kasa P. 2001. Reversible and irreversible cholinesterase inhibitors cause changes in neuronal amyloid precursor processing and protein kinase C level in vitro. Neurochem Int, 38:219-26.
170. Paleacu D, Mazeh D, Mirecki I, et al. 2002. Dorepezil for the treatment of behavioral symptoms in patients with Alzheimer's disease. Clin Neuropharmacol, 25:313-7.
171. Parnetti L, Amici S, Lanari A, et al. 2002. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. Neurol Sci, 23 (Suppl 2): S95-6.
172. Periclou AP, Ventura D, Sherman T, et al. 2004. Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. Ann Pharmacother, 38:1389-94.
173. Passmore AP, Bayer AJ, Steinhagen-Thiessen E. 2005. Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials. J Neurol Sci, 229-230:141-6.
174. Petersen RC, Smith GE, Waring SC, et al. 1999. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol, 56:303-8.
175. Petersen RC, Thomas RG, Grundman M, et al. 2005. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med, 352:2379-88.
176. Poirier J. 1999. Apolipoprotein FA, cholinergic integrity and the pharmacogenetics of Alzheimer's disease. J Psychiat Neurosci, 24:147-53.
177. Poirier J, Delisle M-C, Quirion R et al. 1995. Apolipoprotein E4 allele as a predictor of cholinergic deficits treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A, 92: 12260-64.
178. Pratt RD. 2003. Patient populations in clinical studies of donepezil in vascular dementia. Int Psychogeriatrics, 15(Suppl 1): 195-200.
179. Rakonczay Z. 2003. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain. Acta Biol Hung, 54:183-9.
180. Raskind MA, Peskind ER, Wessel T, et al. 2000. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-I Study Group. Neurology, 54:2261-68.
181. Ravic M, Warrington S, Boyce M, et al. 2004. Repeated dosing with donepezil does not affect the safety, tolerability or pharmacokinetics of single-dose thioridazine in young volunteers. Br J Clin Pharamcol, 58 (Suppl 1):34-40.
182. Rawls WN. 2005. Donepezil in more advanced Alzheimer's disease. Consult Pharm, 20:592-600.
183. Reale M, Iarlori C, Gambi F, et al. 2005. Acetylcholinesterase inhibitors effects on oncostatin-M, interleukin-1 beta and interleukin-6 release from lymphocytes of Alzheimer's disease patients. Exp Gerontol, 40:165-71.
184. Reyes JF, Preskorn SH, Khan A, et al. 2004. Concurrent administration of donepezil HCI and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses. Br J Clin Pharamcol, 58(SuppI 1):50-7.
185. Rigaud AS, Traykov L, Latour F, et al. 2002. Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease. Pharmacogenetics, 12:415-20.
186. Ritchie CW, Ames D, Clayton T, et al. 2004. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry, 12:358-69.
187. Rodriguez G, Vitali P, De Leo C, et al. 2002. Quantitative EEG changes in Alzheimer patients during long-term donepezil therapy. Neuropsychobiology, 46:49-56.
188. Rogers SL. 1998. Perspectives in the management of Alzheimer's disease: clinical profile of donepezil. Dement Geriat Cogn Disord, 9(Suppl 3):29-42.
189. Rogers SL, Friedhoff LT. 1996. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia, 7:293-303.
190. Rogers SL, Doody RS, Molis RC, et al. 1998a. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med, 158:1021-31.
191. Rogers SL, Doody RS, Pratt RD, et al. 2000. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol, 10: 195-203.
192. Rogers SL, Farlow MR, Doody RS, et al. 1998b. A 24-week, double-blind placebo-controlled trial with donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology, 50:136-45.
193. Roman GC, Wilkinson DG, Doody RS, et al. 2005. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. Dement Geriatr Cogn Disord, 20:338-44.
194. Rozzini L, Vicini Chilovi B, Bellelli G, et al. 2005. Effecys of cholinesterase inhibitors appear greater in patients on estabilized. antihypertensive therapy. Int J Geriatr Psychiatry, 20:547-51.
195. Salloway S, Ferris S, Kluger A, et al. 2004. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology, 63:651-7.
196. Salloway SP, Kumar D, Ieni J, et al. 2003. Benefits of donepezil treatment in patients with mild cognitive impairment. Neurology, 60(Suppl 1):A411-12.
197. Sánchez Morillo J, Demartini Ferrari A, Roca de Togores López A. 2003. Interaction of donepezil and muscular blockers in Alzheimer's disease. Rev Esp Anestesiol Reanim, 50:97-100.
198. Sano M. 2004. Economic effect of cholinesterase inhibitor therapy: implications for managed care. Manag Care Interface 17:44-9.
199. Scheltens P, Fox NC, Bartkhof F, et al. 2004. Effect of galatamine treatment on brain atrophy as assessed by MRI in patients with mild cognitive impairment. Neurobiol Aging, 25:S270-1.
200. Schindler RJ. 2005. Dementia with cerebrovascular disease: the benefits of early intervention. Eur J Neurol, 12(Suppl 3):17-21.
201. Selkoe DJ, Podlisny MB. 2002. Deciphering the genetic basis of Alzheimer's disease. Annu Rev Genomics Hum Genet, 3:67-99.
202. Seltzer B. 2005. Donepezil in the treatment of dementia. Aging Health, 1:7-17.
203. Seltzer B, Zolnouni P, Nunez M, et al. 2004. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch Neurol, 61:1852-6.
204. Shaw KT, Utsuki T, Rogers J. 2001. Phenserine regulates translation of beta-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Natl Acad Sci USA, 98:7605-10.
205. Shimizu S, Hanyu H, Iwamoto T, et al. 2006. SPECT follow-up study of cerebral blood flow changes during donepezil therapy in patients with Alzheimer's disease. J Neuroimaging, 16:16-23.
206. Singer M, Romero B, Koenig E, et al. 2005. Nigtmares in patients with Alzheimer's disease caused by donepezil. Therapeutic effect depends on the time of intake. Nervenartz, 76:1127-9.
207. Sjögren M, Hesse C, Basun H, et al. 2001. Tacrine and rate of progression in Alzheimer's disease-relation to ApoE allele genotype. J Neural Transm, 108:451-8.
208. Sonkusare S, Srinivasen K, Kaul C, et al. 2005. Effect of donepezil and lercanidipine on memory impairment induced by intracerebroventricular streptozotozin in rats. Life Sci, 77:1-14.
209. Sortino MA, Frasca G, Chisari M, et al. 2004. Novel neuronal targets for the acetylcholinesterase inhibitor donepezil. Neuropharmacology, 47:1198-204.
210. Stahl SM, Markowitz JS, Gutterman EM, et al. 2003. Co-use of donepezil and hypnotics among Alzheimer's disease patients in the community. J Clin Psychiatry, 64:466-72.
211. Standridge JB. 2004. Donepezil did not reduce the rate of institutionalization or disability in people with mild to moderate Alzheimer's disease. Evid Based Ment Health, 7:112.
212. Stirling Meyer J, Li Y, Xu G, et al. 2002. Feasibility of treating mild cognitive impairment with cholinesterase inhibitors. Int J Geriat Psychiatry, 17:586-8.
213. Sugimoto H, Iimura Y, Yamanishi Y, et al. 1995. Sintesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl]methylpiperidine hydrochloride and related compounds. J Med Chem, 38:4821-9.
214. Sugimoto H, Ogura H, Arai Y, et al. 2002. Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor. Jpn J Pharmacol, 89:7-20.
215. Sub Y-H, Checler F. 2002. Amyloid precursor protein, presenilins, and α-synuclein: Molecular pahogenesis and pharmacological applications in Alzheimer's disease. Pharmacol Rev, 54:469-525.
216. Summers WK, Majovski LV, Marsh GM, et al. 1986. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med, 315:12141-5.
217. Takeda A, Loveman E, Clegg A, et al. 2006. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. Int J Geriatr Psychiatry, 21:17-28.
218. Tanaka Y, Hanyu H, Sakurai H, et al. 2003a. Characteristics of MRI features in Alzheimer's disease patients predicting response to donepezil treatment. Nippon Ronen Igakkai Zasshi, 40:261-6.
219. Tanaka Y, Hanyu H, Sakurai H, et al. 2003b. Atrophy of the substantia innominata on magnetic resonance imaging predicts response to donepezil treatment in Alzheimer's disease patients. Dement Geritar Cogn Disord, 16:119-25.
220. Tariot PN, Cummings JL, Katz IR, et al. 2001. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc, 49:1590-9.
221. Tariot PN, Farlow MR, Grossberg GT, et al. 2004. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA, 291:317-24.
222. Thomas DA, Libon DJ, Ledakis GE. 2005. Treating dementia patients with vascular lesions with donepezil: a preliminary analysis. Appl Neuropsychol, 12:12-8.
223. Tiseo PJ, Foley K, Friedhooff LT. 1998a. The effect of multiple doses of donepezil HCI on the pharmacokinetic and pharmacodynamic proffle of warfarin. Br J Clin Pharmacol, 46 (Suppl 1):45-50.
224. Tiseo PJ, Perdomo CA, Friedhoff LT. 1998b. Concurrent administration of donepezil HCI and digoxin: assessment of pharmacokinetic changes. Br J Clin Pharmacol, 46 (Supp 1):40-4.
225. Tiseo PJ, Foley K, Friedhoof LT. 1998c. Concurrent administration of donepezil HCI and theophylline: assessment of pharmacokinetic changes following multiple-dose administration in healthy volunteers. Br J Clin Pharmacol, 46 (Suppl 1):35-9.
226. Tigeo PJ, Perdomo CA, Friedhoff LT. 1998d. Concurrent administration of donepezil HCI and cimetidine: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol, 46 (Suppl 1):25-9.
227. Tigeo PJ, Perdomo CA, Friedhoff LT. 1998e. Concurrent administration of donepezil HCI and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol, 46 (Suppl 1):30-4.
228. Tiseo PJ, Perdomo CA, Friedhoff LT. 1998f. Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study. Br J Clin Pharmacol, 46 (Suppl 1): 19-24.
229. Touchon J, Bergman H, Bullock R, et al. 2006. Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology. Curr Med Res Opin, 22:49-59.
230. Trinh NH, Hoblyn J, Mohanty S, et al. 2003. Efficacy of cholinesterase iiihibitors in the treatment of neuropsychiatric symptoms and functional unpairment in Alzheimer's disease: a meta-analysis. JAMA, 289:210-16.
231. Tumiatti, V, Andrisano V, Banzi R, et al. 2004. Structure-activity relationship of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 3. Effect of replacing the inner polymethylene chain with cyclic moieties. J Med Chem, 47:6490-8.
232. Ueki A, Iwado H, Shinjo H, et al. 2001. Malignant syndrome caused by a combination of bromperidol and donepezil hydrochloride in a patients with probable dementia with Lewy bodies. Nippon Ronen Igakkai Zasshi, 38:822-4.
233. Van Dyck CH, Schmitt FA, Olin IT, Memantine MEM-MD-02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. Am J Geriatr Psychiatry, 14:428-37.
234. Verrico MM, Nace DA, Towers AL. 2000. Fulminant chemical hepatitis possibly associated with donepezil and sertraline therapy. J Am Geriatr Soc, 48:1659-63.
235. Wang LN, Wang W, Zhang XL, et al. 2004. An interventional study on amnestic mild cognitive impairment with small dose donepezil. Zhonghua Nei Ke Za Zhi, 43:760-3.
236. Weinshilboum R. 2003. Inheritance and drug response. N Engl J Med, 348:529-37.
237. Weinshilboum RM, Wang L. 2006. Pharmacogenetics and pharmacogenomics: Development, science, and translation. Annu Rev Genomics Hum Genet, 7:223-45.
238. Weiser M, Davidson M, Hartmann R. 2002. A pilot randomized, open-label trial assessing safety and pharmacokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances. Int J Geriat Psychiatry, 17:343-6.
239. Werber AE, Klein C, Rabey JM. 2001. Evaluation of cholinergic treatment in demented patients by P300 evoked related potentials. Neurol Neurochir Pol, 35(Suppl 3):37-43.
240. Wheeler SD. 2006. Donepezil treatment of topiramate-related cognitive dysfunction. Headache, 46:332-5.
241. Whitehead A, Perdomo C, Pratt RD, et al. 2004. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials. Int J Geriatr Psychiatry, 19:624-33.
242. Whitehouse P, Price DL, Strubel RG, et al. 1982. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science, 215:1237-9.
243. Wilkinson DG. 1999. The pharmacology of donepezil: a new treatment of Alzheimer's disease. Expert Opin Pharmacother, 1: 121-35.
244. Wilkinson D, Doody R, Helme R, et al. 2003. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology, 61:479-86.
245. Wilkinson DG, Passmore AP, Bullock R, et al. 2002. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract, 56:441-6.
246. Wimo A. 2004. Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer's disease: a review with methodological considerations. Drug Aging, 21:279-95.
247. Wimo A, Winblad B, Engedal K, et al. 2004. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial. Dement Geriatr Cogn Disord, 15:44-54.
248. Winblad B, Engedal K, Soinimen H, et al. 2001. A 1-year, randomized, placebo-controlled study of donepezil in patients with midl to moderate AD. Neurology, 57:489-95.
249. Winblad B, Kilander L, Eriksson S, et al. 2006a. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet, 367:1057-65.
250. Winblad B Wimo A, Engedal K, et al. 2006b. 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord, 21:353-63.
251. Wisor JP, Edgar DM, Yesavage J, et al. 2005. Sleep and circadian abnormalities in a transgenic mouse model of Alzheimer's disease: a Tole for cholinergic transmission. Neuroscience, 131:375-85.
252. Xiong G, Doraiswamy PM. 2005. Combination drug therapy for Alzheimer's disease: what is evidence-based, and what is not? Geriatrics, 60:22-6.
253. Yasui-Furukori N, Furukori H, Kaneda A, Kaneko S, Tateishi T. 2004. The effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of donepezil. J Clin Pharmacol, 44:538-42.
254. Yorston GA, Gray R. 2000. Hypnopompic hallucinations with donepezil. J Psychopharmacol, 14:303-4.
255. Yu B, Hu GY 2005. Donepezil blocks voltage-gated ion channels in rat dissociated hippocampal neurons. Eur J Pharmacol, 508:15-21.
256. Zhang L, Zhou FM, Dani JA. 2004. Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release. Mol Pharmacol, 66:538-44.
257. Zhao Q, Xie C, Pesco-Koplowitz L, et al. 2003. Pharmacokinetic and safety assessment of concurrent administration of risperidone and donepezil. J Clin Pharmacol, 43:180-6.